WASHINGTON (AP) — A new strategy to fight an extremely aggressive type of brain tumor showed promise in a pair of experiments with a handful of patients. Scientists took patients’ own immune cells and turned them into “living drugs” able to recognize and attack glioblastoma. In the first-step tests, those cells shrank tumors at least temporarily, researchers reported Wednesday. So-called CAR-T therapy already is used to fight blood-related cancers like leukemia but researchers have struggled to make it work for solid tumors. Now separate teams at Massachusetts General Hospital and the University of Pennsylvania are developing next-generation CAR-T versions designed to get past some of glioblastoma’s defenses. “It’s very early days,” cautioned Penn’s Dr. Stephen Bagley, who led one of the studies. But “we’re optimistic that we’ve got something to build on here, a real foundation.” |
Hundreds of lizards seized in Australia police bustMideast tensions loom ahead of Biden meeting with Iraqi PM alChina's Hubei eases coronavirus curbsGovernment likened to 'dinosaurs behaving as though it's 1948' over te reo Māori useWorldwide virus deaths exceed 18,800HKFP Lens: 'Dear Hong Kong' celebrates city's diversity with new photo bookGovernment holds first carbon auction of the year after four failuresGreens in 'defensive mode' over Golriz Ghahraman allegationsChina passes Hong Kong security billMideast tensions loom ahead of Biden meeting with Iraqi PM al